Trio Inhalation Capsule 25 mcg+200 mcg+62.5 mcg is a triple-combination therapy containing Vilanterol Trifenatate, Fluticasone Furoate, and Umeclidinium Bromide, designed for the management of chronic obstructive pulmonary disease (COPD) and severe asthma in adults. This formulation provides a higher dose of Fluticasone Furoate (200 mcg) for enhanced anti-inflammatory action while maintaining bronchodilation and airway relaxation for better symptom control.

• Vilanterol Trifenatate (25 mcg): A long-acting beta-2 agonist (LABA) that relaxes airway smooth muscles, improving airflow.
• Fluticasone Furoate (200 mcg): A potent inhaled corticosteroid (ICS) that reduces airway inflammation and swelling.
• Umeclidinium Bromide (62.5 mcg): A long-acting muscarinic antagonist (LAMA) that prevents bronchoconstriction and enhances bronchodilation.

This combination provides once-daily convenient therapy that targets multiple mechanisms to control symptoms, reduce exacerbations, and improve lung function.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Trio Inhalation Capsule 25 mcg+200 mcg+62.5 mcg is indicated for:

• Maintenance treatment of moderate to severe COPD
• Adults with severe asthma inadequately controlled with dual therapy
• Patients with frequent exacerbations despite standard inhaled therapy
• Improving respiratory function, reducing shortness of breath, and preventing flare-ups

Mechanism of Action

The three components act synergistically:

• Vilanterol Trifenatate (LABA): Stimulates beta-2 adrenergic receptors, relaxing airway muscles and improving airflow.
• Fluticasone Furoate (ICS): Reduces airway inflammation, mucus production, and hyperreactivity, controlling symptoms.
• Umeclidinium Bromide (LAMA): Blocks muscarinic receptors, preventing bronchoconstriction and promoting sustained bronchodilation.

Together, this triple therapy improves lung function, reduces exacerbations, and enhances overall respiratory health.

Dosage and Administration

• Recommended dose: 1 inhalation capsule once daily, preferably at the same time each day
• Use with the prescribed dry powder inhaler (DPI) device
• Capsules must be inhaled, not swallowed
• Rinse mouth after inhalation to reduce the risk of oral thrush
• Not suitable for acute relief of sudden breathing difficulties

Benefits

• Provides potent anti-inflammatory action with higher Fluticasone dose
• Reduces frequency and severity of COPD and asthma exacerbations
• Improves breathing, lung function, and exercise tolerance
• Targets multiple pathways: bronchodilation, anti-inflammatory action, and airway relaxation
• Convenient once-daily dosing improves adherence

Side Effects

Common side effects may include:

• Throat irritation, hoarseness, or cough
• Oral fungal infections (thrush)
• Headache or mild dizziness
• Dry mouth

Rare but serious side effects:

• Paradoxical bronchospasm
• Rapid heart rate or palpitations
• Severe allergic reactions

Seek immediate medical attention if severe breathing difficulty, allergic reactions, or heart-related symptoms occur.

Precautions and Warnings

• Not for use as a rescue inhaler
• Use with caution in patients with cardiovascular disease, glaucoma, or urinary retention
• Monitor for adrenal suppression or pneumonia with long-term corticosteroid use
• Pregnancy and breastfeeding: only use if clearly indicated under medical supervision
• Ensure correct inhaler technique to maximize therapeutic effect

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

Trio may interact with:

• Other beta-agonists (may increase heart rate or blood pressure)
• Strong CYP3A4 inhibitors (may elevate corticosteroid levels)
• Anticholinergic medications (additive effects)

Always inform your healthcare provider about all medications and supplements before starting therapy.

Storage

• Store below 30°C in a dry place
• Keep capsules in the blister pack until use
• Protect from moisture and direct sunlight
• Keep out of reach of children
• Do not use after the expiration date.